149 related articles for article (PubMed ID: 36640141)
1. Immune Checkpoint Therapy Combinations in Adult Advanced MiT Family Translocation Renal Cell Carcinomas.
Alhalabi O; Thouvenin J; Négrier S; Vano YA; Campedel L; Hasanov E; Bakouny Z; Hahn AW; Bilen MA; Msaouel P; Choueiri TK; Viswanathan SR; Sircar K; Albiges L; Malouf GG; Tannir NM
Oncologist; 2023 May; 28(5):433-439. PubMed ID: 36640141
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas.
Thouvenin J; Alhalabi O; Carlo M; Carril-Ajuria L; Hirsch L; Martinez-Chanza N; Négrier S; Campedel L; Martini D; Borchiellini D; Chahoud J; Lodi M; Barthélémy P; Hasanov E; Hahn AW; Gil T; Viswanathan SR; Bakouny Z; Msaouel P; Asim Bilen M; Choueiri TK; Albiges L; Tannir NM; Malouf GG
Oncologist; 2022 Dec; 27(12):1041-1047. PubMed ID: 35979929
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders.
Boilève A; Carlo MI; Barthélémy P; Oudard S; Borchiellini D; Voss MH; George S; Chevreau C; Landman-Parker J; Tabone MD; Chism DD; Amin A; Bilen MA; Bosse D; Coulomb-L'hermine A; Su X; Choueiri TK; Tannir NM; Malouf GG
J Immunother Cancer; 2018 Dec; 6(1):159. PubMed ID: 30591082
[TBL] [Abstract][Full Text] [Related]
4. Systemic Therapy in Patients With Metastatic Xp11.2 Translocation Renal Cell Carcinoma.
Yan X; Zhou L; Li S; Wu X; Cui C; Chi Z; Si L; Kong Y; Tang B; Li C; Mao L; Wang X; Lian B; Bai X; Dai J; Guo J; Sheng X
Clin Genitourin Cancer; 2022 Aug; 20(4):354-362. PubMed ID: 35387755
[TBL] [Abstract][Full Text] [Related]
5. MiTF/TFE Translocation Renal Cell Carcinomas: From Clinical Entities to Molecular Insights.
Simonaggio A; Ambrosetti D; Verkarre V; Auvray M; Oudard S; Vano YA
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35886994
[TBL] [Abstract][Full Text] [Related]
6. Treatment Outcomes in Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid and/or Rhabdoid Dedifferentiation After Progression on Immune Checkpoint Therapy.
Hahn AW; Surasi DS; Viscuse PV; Bathala TK; Wiele AJ; Campbell MT; Zurita AJ; Shah AY; Jonasch E; Gao J; Goswami S; Alhalabi O; Rao P; Sircar K; Tannir NM; Msaouel P
Oncologist; 2024 May; 29(5):392-399. PubMed ID: 38035767
[TBL] [Abstract][Full Text] [Related]
7. [MiT family translocation renal cell carcinomas: Natural history, molecular features and multidisciplinary management].
Herrscher H; Boilève A; Lindner V; Barthélémy P; Hutt É; Pierard L; Kurtz JE; Rioux-Leclercq N; Lang H; Malouf GG
Bull Cancer; 2020 Feb; 107(2):272-280. PubMed ID: 32044098
[TBL] [Abstract][Full Text] [Related]
8. Predictive genomic markers of response to VEGF targeted therapy in metastatic renal cell carcinoma.
Stenehjem DD; Hahn AW; Gill DM; Albertson D; Gowrishankar B; Merriman J; Agarwal AM; Thodima V; Harrington EB; Au TH; Maughan BL; Houldsworth J; Pal SK; Agarwal N
PLoS One; 2019; 14(1):e0210415. PubMed ID: 30682039
[TBL] [Abstract][Full Text] [Related]
9. Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network.
Malouf GG; Camparo P; Oudard S; Schleiermacher G; Theodore C; Rustine A; Dutcher J; Billemont B; Rixe O; Bompas E; Guillot A; Boccon-Gibod L; Couturier J; Molinié V; Escudier B
Ann Oncol; 2010 Sep; 21(9):1834-1838. PubMed ID: 20154303
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy.
Graham J; Wells JC; Dudani S; Gan CL; Donskov F; Lee JL; Kollmannsberger CK; Meza L; Beuselinck B; Hansen A; North SA; Bjarnason GA; Sayegh N; Kanesvaran R; Wood LA; Hotte SJ; McKay RR; Choueiri TK; Heng DYC
Eur J Cancer; 2022 Aug; 171():124-132. PubMed ID: 35717820
[TBL] [Abstract][Full Text] [Related]
11. Phenotypical screening on metastatic PRCC-TFE3 fusion translocation renal cell carcinoma organoids reveals potential therapeutic agents.
Cao C; Lan X; Shang B; Jiang W; Guo L; Zheng S; Bi X; Zhou A; Sun Z; Shou J
Clin Transl Oncol; 2022 Jul; 24(7):1333-1346. PubMed ID: 35118587
[TBL] [Abstract][Full Text] [Related]
12. Systemic Treatments for Metastatic Renal Cell Carcinoma: 10-Year Experience of Immunotherapy and Targeted Therapy.
Kim SH; Park WS; Kim SH; Joung JY; Seo HK; Lee KH; Chung J
Cancer Res Treat; 2016 Jul; 48(3):1092-101. PubMed ID: 26875203
[TBL] [Abstract][Full Text] [Related]
13. VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib.
Scartozzi M; Bianconi M; Faloppi L; Loretelli C; Bittoni A; Del Prete M; Giampieri R; Maccaroni E; Nicoletti S; Burattini L; Minardi D; Muzzonigro G; Montironi R; Cascinu S
Br J Cancer; 2013 Mar; 108(5):1126-32. PubMed ID: 23511629
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of fourth-line targeted therapy in patients with metastatic renal cell carcinoma: a retrospective analysis.
Ralla B; Erber B; Goranova I; von der Aue L; Floercken A; Hinz S; Kempkensteffen C; Magheli A; Miller K; Busch J
World J Urol; 2016 Aug; 34(8):1147-54. PubMed ID: 26676614
[TBL] [Abstract][Full Text] [Related]
15. First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium.
Dudani S; Graham J; Wells JC; Bakouny Z; Pal SK; Dizman N; Donskov F; Porta C; de Velasco G; Hansen A; Iafolla M; Beuselinck B; Vaishampayan UN; Wood LA; Liow E; Yan F; Yuasa T; Bjarnason GA; Choueiri TK; Heng DYC
Eur Urol; 2019 Dec; 76(6):861-867. PubMed ID: 31445844
[TBL] [Abstract][Full Text] [Related]
16. Newly designed break-apart and ASPL-TFE3 dual-fusion FISH assay are useful in diagnosing Xp11.2 translocation renal cell carcinoma and ASPL-TFE3 renal cell carcinoma: a STARD-compliant article.
Chen X; Yang Y; Gan W; Xu L; Ye Q; Guo H
Medicine (Baltimore); 2015 May; 94(19):e873. PubMed ID: 25984679
[TBL] [Abstract][Full Text] [Related]
17. Effect of Antibiotic Use on Outcomes with Systemic Therapies in Metastatic Renal Cell Carcinoma.
Lalani AA; Xie W; Braun DA; Kaymakcalan M; Bossé D; Steinharter JA; Martini DJ; Simantov R; Lin X; Wei XX; McGregor BA; McKay RR; Harshman LC; Choueiri TK
Eur Urol Oncol; 2020 Jun; 3(3):372-381. PubMed ID: 31562048
[TBL] [Abstract][Full Text] [Related]
18. Detection of 6 TFEB-amplified renal cell carcinomas and 25 renal cell carcinomas with MITF translocations: systematic morphologic analysis of 85 cases evaluated by clinical TFE3 and TFEB FISH assays.
Skala SL; Xiao H; Udager AM; Dhanasekaran SM; Shukla S; Zhang Y; Landau C; Shao L; Roulston D; Wang L; Siddiqui J; Cao X; Magi-Galluzzi C; Zhang M; Osunkoya AO; Smith SC; McKenney JK; Betz BL; Myers JL; Chinnaiyan AM; Tomlins SA; Mehra R
Mod Pathol; 2018 Jan; 31(1):179-197. PubMed ID: 28840857
[TBL] [Abstract][Full Text] [Related]
19. Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study.
Colomba E; Le Teuff G; Eisen T; Stewart GD; Fife K; Larkin J; Biondo A; Pickering L; Srinivasan A; Boyle H; Derosa L; Sternberg CN; Recine F; Ralph C; Saldana C; Barthélémy P; Bernhard JC; Gurney H; Verhoest G; Vauleon E; Bigot P; Berger J; Pfister C; Gravis G; Rodier JM; Culine S; Caty A; Rolland F; Priou F; Escudier B; Albiges L
Eur J Cancer; 2017 Jul; 80():55-62. PubMed ID: 28549248
[TBL] [Abstract][Full Text] [Related]
20. Incidence, clinicopathological features and fusion transcript landscape of translocation renal cell carcinomas.
Classe M; Malouf GG; Su X; Yao H; Thompson EJ; Doss DJ; Grégoire V; Lenobin J; Fantoni JC; Sudour-Bonnange H; Khayat D; Aubert S; Tannir NM; Leroy X
Histopathology; 2017 Jun; 70(7):1089-1097. PubMed ID: 28106924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
